Compare Exelixis Inc. Common Stock (EXEL) vs Weyerhaeuser Company Common Stock (WY) Price & Performance

EXEL trades at $59.51, down 0.52% on the day but near its 52-week high of $61.66 reached on October 12, 2026. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent news highlights include a three-month FDA review delay for zanzalintinib but continued growth in CABOMETYX revenue, which surpassed $3 billion annually.

The outlook remains positive with strong profitability metrics (35.33% net margin, 44.39% ROE) and projected revenue growth to $2.4 billion in 2026. Key risks include regulatory delays for new drug approvals and competitive pressures in oncology. Analyst consensus is mixed with 48% buy ratings but a price target of $52.33 suggesting potential downside from current levels.

Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.

Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.